Frequency of Hematological Response in Patients with Chronic Myeloid Leukemia (Chronic Phase) with Imatinib After Three Months Presenting to CMH Rawalpindi
DOI:
https://doi.org/10.51253/pafmj.v74i2.7036Keywords:
Chronic Myeloid Leukemia, Chronic Phase, Imatinib MesylateAbstract
Objective: To find the frequency of haematological response in patients of chronic myeloid leukaemia (Chronic Phase) after three months of Imatinib Mesylate therapy, presenting to CMH Rawalpindi
Study Design: Cross-sectional study.
Place and Duration of Study: Department of Oncology Combined Military Hospital, Rawalpindi Pakistan, from Jan to Jun 2020.
Methodology: Forty-six patients aged 18 and above within the chronic phase of CML were included. Patients underwent detailed clinical history, examination, baseline investigations, and bone marrow studies at presentation. Enrolled patients were given 400mg of Imatinib, and a complete haematological response was noted at the end of 3 months of therapy.
Results: In our study, the age of patients ranged from 18 to 67 years, with a mean age of 47.2+10.6 years. 33(71.7%)were male, and 13(28.3%) were female. 42(91.3%) patients achieved complete haematological response to Imatinib at three months of therapy. Adverse drug reactions exhibited were oedema 18(39.1%), gastrointestinal disturbance 12(26.1%), anaemia 05(10.9%), and skin reactions 03(6.5%).
Conclusion: This study has concluded that Imatinib Mesylate is highly effective in treating chronic phase CML at the
haematological level and can be considered the drug of first choice in CML-CP.
Downloads
References
Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters
RS, Talpaz M, et al. Chronic myelogenous leukemia: a
multivariate analysis of the associations of patient characteristics
and therapy with survival. Blood 1985 ; 66(6): 1326-1335.
Meyran D, Petit A, Guilhot J, Suttorp M, Sedlacek P, De Bont E,
et al. Lymphoblastic predominance of blastic phase in children
with chronic myeloid leukaemia treated with imatinib: A report
from the I-CML-Ped Study. Eur J Cancer 2020; 137: 224-234.
https://doi.org/10.1016/j.ejca.2020.06.024
Wajid AA, Zeeshan M, Mehmood F, Sharif I, Umair M, Ali A.
Early Molecular Response with Imatinib Therapy in Chronic
Myeloid Leukemia and Its Association with Baseline White
Blood Cell Count and Spleen Size. Pak Armed Force Med J 2018:
(5): 1199-1204.
Khan A, Ahmed R, Fatimah S, Nadeem M, Iqbal S, Gilani ST, et
al. The High BCR-ABL1 Gene Percentage At Time Of
Presentation: A Tool To Predict Failure In Achieving Early
Molecular Response In Chronic Myeloid Leukemia (CML): A
Tertiary Care Center Experience.Pak Armed Force Med J 2021;
(1): 71-75. https://doi.org/10.51253/pafmj.v71iSuppl-1.3891
Ejele OA, Omunakwe HE, Iyalla C, da Lilly-Tariah OB, PedroEgbe CN. Visual and auditory complications of chronic myeloid
leukemia: a case report. J Adv Med Res 2013; 27(3): 566-572.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S,
Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment
for Chronic Myeloid Leukemia. N Engl J Med 2017 ; 376(10): 917-
https://doi.org/10.1056/NEJMoa1609324
Di Felice E, Roncaglia F, Venturelli F, Mangone L, Luminari S,
Cirilli C, et al. The impact of introducing tyrosine kinase
inhibitors on chronic myeloid leukemia survival: a populationbased study. BMC Cancer 2018; 18(1): 1069.
https://doi.org/10.1186/s12885-018-4984-3
Banjar H, Ranasinghe D, Brown F, Adelson D, Kroger T,
Leclercq T, et al. Modelling predictors of molecular response to
frontline Imatinib for patients with chronic myeloid Leukaemia.
PLoS One 2017; 12(1): e0168947
. https://doi.org/10.1371/journal.pone.0168947
Amouei A, Daeian N, Khezrnia SS, Mansouri A, Hadjibabaie M.
Imatinib Efficacy, Safety and Resistance in Iranian Patients with
Chronic Myeloid Leukemia: A Review of Literature. Int J
Hematol Oncol Stem Cell Res 2021; 15(2): 114-131.
https://doi.org/10.18502/ijhoscr.v15i2.6042
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021.
CA Cancer J Clin 2021; 71(1): 7-33.
https://doi.org/10.3322/caac.21654
Druker BJ, Sawyers CL, Kantarjian H. Activity of a specific
inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of
chronic myeloid leukemia and acute lymphoblastic leukemia
with the Philadelphia chromosome N Engl J Med 2001; 344(14):
-1042. https://doi.org/10.1056/NEJM200104053441402
Tardieu S, Brun‐Strang C, Berthaud P, Michallet M, Guilhot F,
Rousselot P, et al. Management of chronic myeloid leukemia in
France: a multicentered cross‐sectional study on 538 patients.
Pharmacoepidemiol Drug Saf 2005; 14(8): 545-553.
https://doi.org/10.1002/pds.1046
Canadeo A, Fournogerakis M, Zook F. A Multi-disciplinary
Approach to Managing Chronic Myelogenous Leukemia
Patients on Oral Anticancer Therapy at a Large Academic
Medical Center. Curr Hematol Malig Rep 2021 ; 16(6): 509-
https://doi.org/10.1007/s11899-021-00659-9
Ejele OA, Omunakwe HE, Iyalla C, da Lilly-Tariah OB, PedroEgbe CN. Visual and auditory complications of chronic myeloid
leukemia: a case report. J Adva Med Med Res 2013; 27(2): 566-72.
https://doi.org/10.9734/BJMMR/2013/2259
Usmani SZ, Yunus SA, Jamal Y. Overview of chronic myeloid
leukemia patients in Pakistan in the pre-imatanib era. Asian Pac
J Cancer Prev 2009; 10(6): 1039-1040.
Aslam HM, Iqbal MS, Merchant AA, Muhammad MG, Yasir J,
Faizee FA, et al. Hematologic Response and Frequency of Side
Effects in Chronic Myeloid Leukemia Patients Treated with
Imatinib (GLIVEC): A South-East Asian Experience.Blood 2017;
(1): 5257.
Mouraa MS, Benevides TCL, Delamaina MT, Duarte GO,
Percout PO, Dias MA, et al. Evaluation of anemia after longterm treatment with imatinib in chronic myeloid leukemia
patients in chronic phase. Hematol Transfus Cell Ther 2019;
(4): 329–334. https://doi.org/10.1016/j.htct.2019.03.006
Malhotra H, Yadav A, Gupta N, Soni S, Singh JK, Malhotra B.
Chronic Myeloid Leukemia (CML) in Adolescents & Young
Adults (AYA): Single Institution 10 Years Experience with 1st
Line Imatinib Mesylate (IM). Blood 2020; 136(1):
Downloads
Published
Issue
Section
How to Cite
